



FORMOSA
LABORATORIES, INC.

Sep. 2024

TWSE 4746

Disclaimer

This material has been prepared by Formosa Laboratories Inc. ("Formosalab").

Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. Formosalab is under no obligation to update or keep current the information contained herein. The information contained in this presentation is Formosalab' s confidential information.

Any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

No representation or warranty, express or implied, is or will be made in or in relation to, and no responsibility or liability is or will be accepted by the Company as to, the accuracy or completeness of this material and any liability therefore is hereby expressly disclaimed.

Statements made in this material include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of Formosalab. Without limiting the foregoing, statements including the words "believes" , "anticipates" , "plans" , "expects" and similar expressions are also forward-looking statements. Forward-looking statements reflect, among other

things, management' s plans and objectives for future operations, current views with respect to future events and future economic performances and projections of various financial items.


These forwardlooking statements involve known and unknown risks, uncertainties and other factors which may cause actual results to differ materially from those implied by such forward-looking statements.

- 
- 2023 & 2024 up-to-Aug Operation Results
 - Business Strategy
 - Business Update



Operation Results

Revenues-2024 YoY 9%




Million NTD

Revenues-2024 up to Aug YoY 9%


	Million NTD	YoY
Polymers	1,069	8%
Vit. D Derivatives	469	-20%
Respiratory Agents	374	24%
CDMO	292	-18%
Anticancer	150	7%
Steroids	105	218%
Others	555	59%
Total	3,014	9%

Product Category



2024 1H Profitability

EPS NTD 1.56
BV per share NTD 62.49





Business Strategy

Integrated RD and Manufacturing

Generic API

- High quality GMP manufacturing
- Stable supply chain management
- Effective output to fulfill customer's demand


Injectable

- Vertical integration
- Supply from development to commercialization stage

CDMO

- One-stop-shop service from drug substance to drug product
- ADC and peptide CDMO

Diversified Alliance to Explore Business Opportunity



Expand oversee market





Key Business

API Products

Anti-cancers

Anti-inflammatory
& Analgesic Agents

MRI Enhancing
Agents

Respiratory Agents

Polymeric Drugs

CNS Agents

Immunomodulators

Steroids

Vit. D Derivatives

Antibiotics

Key API Products

- Improve throughput
- Expand manufacture capacity
- Stable supply chain



Highlight

- Polymer products stay strong market share. The whole year forecast remains positive.
- Respiratory API sales keeps growing on revenue.
- Steroid products enter originator' s supply chain and deliver to client steadily.
- Vitamin D products slightly delayed to deliver to clients. The whole year forecast remains.
- Anti-Cancer products keep contributing revenue from new market and new clients.

Comprehensive CDMO Service-One Stop Shop




Comprehensive CDMO Service-One Stop Shop



- Clients includes clinical stages and commercial supply in different territories
- Stable CMO supply to originator in Japan, Europe, and US. New projects are under discussion
- Completes the acquisition of Synchem to expand North American CDMO footprint. Two projects are ongoing and few projects are under discussion.
- Multiple projects enter validation and/or commercial manufacturing

Once stop ADC services



Service scope

- Linker-payload, conjugation, and process development
- ADC candidate screening platform
- Scale-up manufacturing. ADC-DS new line completes validation. The new line can support commercial supply.
- Comprehensive analytic services

ADC CDMO highlight

- Clients include US, Europe, and Taiwan
- Support European client from RD to clinical trial material for Phase I trial. Patient enrollment is ongoing. Scale-up manufacturing is under discussion.
- New ADC DS and DP has completed and delivered to client for phase I global clinical trial.
- Few ADC and peptide projects are ongoing.
- Synchem-Formosa will expand laboratories and early stage bio-conjugation line to fulfill North American CDMO market demand.

Advanced Technology

- Build up Peptide Synthesis Laboratory with automatic solid-phase microwave synthesis for CDMO and Formosa's product development
- Set up microfluidic reactor for API products and CDMO services. The commercial line will be ready 2025 H2.



Injectable Plant Status

- Authority inspection is ongoing
 - Cytotoxic line
 - TFDA: 2022Q2 completed
 - FDA: 2024 Passed first FDA on-site GMP inspection held in July 2024.
 - EMA: Expected 2025Q1 on-site GMP inspection.
 - General line
 - TFDA: 2024/08 completed inspection.
Expected to receive certificate by end of 2024.
 - FDA: 2025
 - Feasible for biologic and chemical drug product in liquid and lyophilization products.
 - Lab-scale injectable filling for clinical trial




Self-development Injectable Products

◆ Eribulin Injectable

(Global market size USD 370 million, US Market USD 130 million, TW market NTD 450 million)

Territory	Status
Turkey	Licensing agreement signed
EU	Licensing agreement signed
US	Agreement to be signed 2024/Q4
Emerging market	- Hong Kong and Pakistan agreement signed - Discussion ongoing

◆ Licensing-out for other self-development injectable products are ongoing



Q & A